down arrow

Coeptis Therapeutics Holdings, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US19207A1088
USD
16.42
0.46 (2.88%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

15.7816.80

52 Week

2.3121.25
Valuation
Technical
Day's Volume

CASH

73.97 k

Shareholding (Mar 2025)

FII

0.07%

Held by 3 FIIs

DII

98.59%

Held by 1 DIIs

Promoter

0.00%

How big is Coeptis Therapeutics Holdings, Inc.?

22-Jun-2025

As of Jun 18, Coeptis Therapeutics Holdings, Inc. has a market capitalization of 28.85 million, with net sales of 0.06 million and a net profit of -11.30 million over the last four quarters. The company's shareholder's funds are 5.29 million, and total assets are 11.01 million as of Dec 24.

Market Cap: As of Jun 18, Coeptis Therapeutics Holdings, Inc. has a market capitalization of 28.85 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Coeptis Therapeutics reported net sales of 0.06 million and a net profit of -11.30 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 5.29 million, while total assets were reported at 11.01 million.

Read More

What does Coeptis Therapeutics Holdings, Inc. do?

22-Jun-2025

Coeptis Therapeutics Holdings, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $3 million as of March 2025, with a market cap of $28.85 million. Key financial metrics include a negative P/E ratio, a dividend yield of 0.00%, and a return on equity of -167.63%.

Overview: Coeptis Therapeutics Holdings, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025). Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025). Market cap: USD 28.85 Million (Micro Cap).<BR><BR>Key Metrics: P/E: NA (Loss Making). Industry P/E: NA. Dividend Yield: 0.00%. Debt Equity: -0.33. Return on Equity: -167.63%. Price to Book: 4.29.<BR><BR>Contact Details: No Company Details Available. Registrar Address: Not available.

Read More

Is Coeptis Therapeutics Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Coeptis Therapeutics Holdings, Inc. shows a mildly bullish trend with conflicting technical indicators, having a year-to-date return of 128.18% but underperforming in the last month with a -14.36% return compared to the S&P 500's 2.33%.

As of 10 September 2025, the technical trend for Coeptis Therapeutics Holdings, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages are bullish, but the monthly RSI indicates a bearish stance. Bollinger Bands show a mildly bullish trend for both weekly and monthly periods. The KST is bullish across both time frames, but the OBV is mildly bearish on a weekly basis. Overall, the indicators suggest a mildly bullish stance with some conflicting signals.<BR><BR>In terms of performance, the stock has had a remarkable year-to-date return of 128.18%, significantly outperforming the S&P 500's 12.22%, but it has underperformed over the past month with a return of -14.36% compared to the S&P 500's 2.33%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 62 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.27

stock-summary
Return on Equity

-214.13%

stock-summary
Price to Book

10.03

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
27.98%
0%
27.98%
6 Months
72.12%
0%
72.12%
1 Year
244.52%
0%
244.52%
2 Years
-28.61%
0%
-28.61%
3 Years
742.05%
0%
742.05%
4 Years
64.86%
0%
64.86%
5 Years
0%
0%
0.0%

Coeptis Therapeutics Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Coeptis Therapeutics Holdings, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Coeptis Therapeutics Holdings, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages are bullish, but the monthly RSI indicates a bearish stance. Bollinger Bands show a mildly bullish trend for both weekly and monthly periods. The KST is bullish across both time frames, but the OBV is mildly bearish on a weekly basis. Overall, the indicators suggest a mildly bullish stance with some conflicting signals. In terms of performance, the stock has had a remarkable year-to-date return of 128.18%, significantly outperforming the S&P 500's 12.22%, but it has underperformed over the past month with a return of -14.36% compared to the S&P 500's 2.33%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
4.73%
EBIT Growth (5y)
-264.05%
EBIT to Interest (avg)
-4.98
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.86%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.67
EV to EBIT
-2.61
EV to EBITDA
-2.89
EV to Capital Employed
6.52
EV to Sales
29.20
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-249.66%
ROE (Latest)
-167.63%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.34%)

Foreign Institutions

Held by 3 Foreign Institutions (0.07%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -43.33% vs 6.25% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.20",
          "val2": "-2.60",
          "chgp": "-61.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.60",
          "val2": "-0.10",
          "chgp": "700.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.30",
          "val2": "-3.00",
          "chgp": "-43.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-22,529.40%",
          "val2": "0.00%",
          "chgp": "-2,252.94%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 48.83% vs 43.35% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.00",
          "val2": "-20.50",
          "chgp": "56.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.10",
          "chgp": "300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.60",
          "val2": "0.60",
          "chgp": "-200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.90",
          "val2": "-21.30",
          "chgp": "48.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.20
0.00
Operating Profit (PBDIT) excl Other Income
-4.20
-2.60
-61.54%
Interest
0.10
0.10
Exceptional Items
0.60
-0.10
700.00%
Consolidate Net Profit
-4.30
-3.00
-43.33%
Operating Profit Margin (Excl OI)
-22,529.40%
0.00%
-2,252.94%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -43.33% vs 6.25% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-9.00
-20.50
56.10%
Interest
0.40
0.10
300.00%
Exceptional Items
-0.60
0.60
-200.00%
Consolidate Net Profit
-10.90
-21.30
48.83%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 48.83% vs 43.35% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Coeptis Therapeutics Holdings, Inc. stock-summary
stock-summary
Coeptis Therapeutics Holdings, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."